Back to Equities

CORT

Corcept Therapeutics Incorporated
Healthcare · Specialty Pharmaceuticals
Gravy Gauge
Is this revenue durable?
Moat Mapper
Is the advantage durable?
Myth Meter
Is sentiment detached from reality?
Fugazi Filter
Are the numbers trustworthy?
Stress Scanner
What breaks under stress?
Insider Investigator
What are insiders telling us?
Black Swan Beacon
What could go catastrophically wrong?
7
Lenses Applied
13
Signals Analyzed
8
Debates Resolved
7
Forecast Markets
The Central Question
"Three of Corcept's Cushing's durability defenses cracked inside 90 days, yet the balance sheet has $532M cash, zero debt, and a newly FDA-approved oncology asset. At ~4x FY26 guide, is the market pricing a fragile revenue stream or a fragile company?"

Corcept Therapeutics is a specialty pharmaceutical company whose FY2025 $761M revenue base is concentrated almost entirely in the Korlym Cushing's syndrome franchise (branded plus authorized generic). Between December 2025 and February 2026, three principal durability defenses degraded materially: the Federal Circuit ruled against Corcept in Teva v. Corcept (patent), the FDA issued a Complete Response Letter on relacorilant for Cushing's (lifecycle extension), and the Q4 specialty pharmacy transition left $65-90M in scripts undispensed (channel). Against that, Lifyorli was approved four months ahead of PDUFA on 2026-03-25 for platinum-resistant ovarian cancer, the balance sheet carries $532M cash with zero debt, and the pipeline spans four SGRA molecules across five-plus indications.

Executive Summary

Cross-lens roll-up assessment

Corcept is mid-transition. The current $761M revenue base is fragile and the fragility is recent rather than structural - three principal Korlym durability defenses degraded inside a 90-day window in late 2025 and early 2026. At the same time, a fortress balance sheet ($532M cash, zero debt, $142M FCF), a four-months-early Lifyorli FDA approval with 7-year orphan exclusivity, and a four-molecule SGRA pipeline provide runway and optionality. The market is pricing multiple adverse scenarios simultaneously at roughly 4x FY26 guide, which the committee reads as over-bearish given the fact pattern - but only if Lifyorli executes and the relacorilant Cushing's CRL resolves via resubmission rather than a new trial.

Higher Scrutiny RequiredMEDIUM confidence

The committee converged on a middle-band readout across every signal: FRAGILE + CONTESTED/DEFENSIBLE boundary + GAP_BEARISH + QUESTIONABLE + MIXED governance + ELEVATED tail risk. None of these are alarming in isolation, but their simultaneity, the recency of the fragility (90-day window), and the binary April 2026 FDA meeting all warrant deeper investigation before any allocation decision. The balance sheet removes going-concern risk, so AVOID is not the right label. But the number of middle-band readings that could tip either direction on Q1 2026 data, the April FDA meeting, Lifyorli Q2/Q3 launch metrics, and the first Form 4 executions under the new 10b5-1 plans argue for HIGHER_SCRUTINY rather than PROCEED_WITH_CAUTION. The UNDERPRICED reading is real but the MEDIUM confidence on it against HIGH confidence on FRAGILE means the asymmetry works only if the 20-25% bear weight holds against the market's implied ~45%.

Key Takeaways

  • REVENUE_DURABILITY is FRAGILE: Three of four principal defenses for the Cushing's franchise weakened in 90 days - Teva Federal Circuit loss on patent (Feb 2026), relacorilant Cushing's CRL on lifecycle extension (Dec 2025), and a specialty pharmacy channel miss that left $65-90M in Q4 2025 scripts undispensed. Authorized generic at 78% of tablet volume adds ongoing per-patient price compression. Lifyorli is a real offset but contributes 'only a small portion' of 2026 per the CFO.
  • FUNDING_FRAGILITY is RESILIENT: $532M cash, zero debt, $142M FY25 FCF, no covenants, no maturities. Under the stress scenario (Korlym -25% + Medicaid compression + sticky SG&A + slow Lifyorli ramp), runway is 4-5 years. Compound-failure scenario compresses runway to roughly 24 months at 10-18% probability. The balance sheet cannot break in any conventional sense.
  • COMPETITIVE_POSITION is DEFENSIBLE (boundary case): Aggregate moat rests on Lifyorli 7-year orphan exclusivity and SGRA platform validation via the four-months-early approval. Per-indication, the revenue-generating Korlym franchise is CONTESTED. Trajectory likely passes through CONTESTED in 2028 as Korlym compression outpaces Lifyorli ramp, then potentially recovers on pipeline milestones (MONARCH, DAZALS).
  • NARRATIVE_REALITY_GAP is GAP_BEARISH while EXPECTATIONS_PRICED is UNDERPRICED: EV/sales of 3.6-4.0x on $900M-$1B FY26 guide implies terminal Cushing's decline, near-zero Lifyorli credit (~$200M vs $500M-$2B comparable), and near-zero pipeline option value. The analyst-constructed market-implied bear weight is ~45% against a fact-pattern-supported 20-25%. Separately, the management narrative runs GAP_BULLISH on the $3-5B relacorilant forecast and 'diversified oncology company' framing.
  • GOVERNANCE_ALIGNMENT is MIXED (two independent lenses): Revenue-only compensation design and 10b5-1 plan-adoption timing by the CFO and endocrinology franchise president 18-22 days pre-CRL create durable optics concerns. Director Baker's $3.3M open-market purchase during active personal litigation, director-level retained stakes of 6.3M shares, zero debt, and no related-party transactions push in the opposite direction. Structural asymmetry - directors retain, officers monetize - is the signal rather than any single transaction.
  • ACCOUNTING_INTEGRITY is QUESTIONABLE (not CONCERNING): A $33.2M tax benefit reduced the visible earnings decline from -59% pre-tax to -29% net. The $245M reported buyback figure includes $72.9M of tax-withholding on equity comp; diluted weighted-average shares still grew 5.7%. A new $2.56M long-term Medicaid rebate accrual appeared at 12/31/2025 coincident with AG reaching 78% volume share. Presentation asymmetries are material but OCF/NI conversion is 1.42, the auditor is EY with an unqualified opinion implied, and no channel stuffing or non-GAAP gamesmanship is present.
  • TAIL_RISK_SEVERITY is ELEVATED: Compound failure scenarios at 7-11% joint probability produce 40-70% equity compression and thesis invalidation. The SGRA mechanism-class safety scenario (4-11% over 18 months) is the single-mechanism concentration risk no ordinary lens owns. A hostile or opportunistic acquisition at a compressed valuation ($27-32) emerged as an adversarially-identified scenario neither analyst originally constructed, with 30-45% conditional probability on a dual-execution or regulatory-plus-governance stress.

Key Tensions

  • FRAGILE current revenue coexists with UNDERPRICED equity. The two are not contradictory - FRAGILE describes the current revenue stream's dependency structure; UNDERPRICED describes market-implied scenario weights against the full fact pattern (balance sheet floor, Lifyorli approval, pipeline breadth). A reader with tighter bear priors would reasonably arrive at FRAGILE + FAIRLY PRICED instead.
  • The aggregate moat is DEFENSIBLE while the franchise generating 100% of 2025 revenue is CONTESTED at the indication level. Aggregate DEFENSIBLE rests on forward-looking Lifyorli orphan exclusivity and platform validation, not backward-looking Korlym franchise defense. If Lifyorli under-delivers in Year 1 (sub-$50M run rate), both the moat and the UNDERPRICED thesis re-rate downward simultaneously.
  • Management narrative runs GAP_BULLISH while market narrative runs GAP_BEARISH. Both are true on different timeframes. Management's $3-5B relacorilant forecast and 'diversified oncology company' framing run ahead of near-term reality; the market's ~$200M Lifyorli credit runs behind the fact pattern. The operative Myth Meter signal is the market gap; management over-statement becomes a qualitative credibility discount on forward forecasts.
  • Capital deployment retrospective is MIXED while point-in-time funding is RESILIENT. The balance sheet absorbs the cost of past deployment quality issues (buyback disclosure gross-up, SG&A front-running the CRL, buybacks at ~$44 while the stock now trades $33-40) without retroactively vindicating them. Both labels coexist stably.
  • The April 2026 FDA meeting on relacorilant Cushing's is binary across multiple signals. Resubmission path improves REVENUE_DURABILITY trajectory, holds DEFENSIBLE, and reduces ELEVATED regulatory exposure. A new-trial requirement strands $80-150M of SG&A buildout, deepens FRAGILE, and pressures DEFENSIBLE toward CONTESTED.

Gravy Gauge

Is this revenue durable?

About this lens

Key Metrics

Revenue Durability
FRAGILE
DURABLE
CONDITIONAL
FRAGILE
ARTIFICIAL
Regulatory Exposure
ELEVATED
MINIMAL
MANAGEABLE
ELEVATED
EXISTENTIAL

Key FindingsClick to expand details

Signal AssessmentsClick for full context

SignalAssessment
Revenue Durability
FRAGILE
Regulatory Exposure
ELEVATED

Model Debates

Cross-Lens Insights

Where Lenses Agree

  • Buyback disclosure gross-up confirmed by Fugazi Filter and Stress Scanner: $245M headline combines $172.9M open-market with $72.9M tax-withholding on equity comp; diluted WA shares still +5.7%; open-market at ~$44 avg vs stock now $33-40
  • Teva Federal Circuit February 2026 loss flagged by Gravy Gauge and Moat Mapper as primary Korlym franchise moat and durability hit; 50-80% of branded revenue at risk on third-party ANDA entry over 12-36 months
  • Director Baker 100K-share open-market buy at $33.14 on 2026-03-17 flagged by Myth Meter, Insider Investigator, and Stress Scanner as substantive alignment signal with partial litigation-optics discount; all three note market is not crediting this
  • Revenue-only 2026 DEF 14A Company Selected Measure identified by Fugazi Filter and Stress Scanner as structural driver of observed 1,440bps operating margin compression over two years - mechanism fingerprinted independently by both lenses
  • Maduck (12/8/2025) and Mokari (12/12/2025) 10b5-1 plan adoption 18-22 days before Cushing's CRL (12/30/2025) flagged by Fugazi Filter and Insider Investigator; cooling-off compliance satisfied but MNPI-at-adoption unresolved from public record
  • New $2.56M long-term accrued government rebate line at 12/31/2025 (vs $0 prior year) coincident with Korlym AG reaching 78% volume share flagged by Fugazi Filter, Stress Scanner, and Gravy Gauge as first visible Medicaid best-price compression signal
  • $532M cash + zero debt + $142M FCF balance sheet confirmed by Gravy Gauge, Stress Scanner, and Moat Mapper as reason FRAGILE/CONTESTED/MIXED middle-band readings do not translate into going-concern risk - provides 4-5 year runway under stress

Where Lenses Differ

REVENUE_DURABILITY vs EXPECTATIONS_PRICED
Gravy Gauge:FRAGILE
Myth Meter:UNDERPRICED

Different objects. FRAGILE describes current revenue stream dependency structure; UNDERPRICED describes market-implied scenario weights given full fact pattern (balance sheet, Lifyorli, pipeline). Myth Meter's explicit read is that bear scenarios are over-weighted at ~45% vs analyst 20-25%.

FUNDING_FRAGILITY vs CAPITAL_DEPLOYMENT
Stress Scanner (Funding):RESILIENT
Stress Scanner (Deployment):MIXED

Temporal decomposition. RESILIENT is point-in-time balance sheet; MIXED is three-year retrospective on deployment quality. The balance sheet absorbs past deployment mistakes (buyback gross-up, SG&A front-running CRL, buybacks at $44 avg vs current $33-40, revenue-only CSM) without retroactively vindicating them.

COMPETITIVE_POSITION (aggregate vs per-indication)
Moat Mapper (aggregate):DEFENSIBLE (boundary, LOW confidence)
Moat Mapper (Korlym franchise):CONTESTED

Lens flags explicitly as boundary case with LOW confidence. Aggregate DEFENSIBLE rests on forward-looking Lifyorli orphan exclusivity plus SGRA platform validation; trajectory predicted to pass through CONTESTED in 2028 trough year before potential pipeline-driven recovery.

NARRATIVE_REALITY_GAP (management vs market)
Myth Meter (management):GAP_BULLISH
Myth Meter (market, operative):GAP_BEARISH

Both gaps are real on different timeframes and audiences. Management narrative ($3-5B relacorilant forecast maintained post-CRL, 'diversified oncology company' framing, 'never been more confident' across three guide cuts) runs ahead of near-term reality. Market narrative (Lifyorli priced as exit opportunity, near-zero pipeline option value) runs behind fact pattern.

GOVERNANCE_ALIGNMENT (insider vs institutional)
Insider Investigator:MIXED (Baker buy vs $11.5M forward Form 144)
Fugazi Filter:MIXED (revenue-only CSM vs no RPT, no dual-class)

Both lenses converge on MIXED from different evidence. Insider Investigator identifies two-tier ownership (directors retain, officers monetize) as the structural signal. Fugazi Filter identifies revenue-only compensation design as the mechanism driving margin compression, offset by clean institutional posture.

The following publicly available documents were collected and extracted into a structured fact dossier that powered this analysis.

SEC Filing
  • Annual Report (10-K) — FY2025
  • Quarterly Report (10-Q) — Q3 2025
  • Quarterly Report (10-Q) — Q2 2025
  • Proxy Statement (DEF 14A) — 2026
  • Current Report (8-K) — Lifyorli FDA Approval (2026-03-25)
  • Current Report (8-K) — Q4 2025 Earnings (2026-02-24)
  • Current Reports (8-K) — 20 filings (May 2024 - March 2026)
  • Form 4 Insider Transactions — 20 filings (Feb-Apr 2026)
  • Form 144 Proposed Sales — 10 filings (Nov 2025-Apr 2026)
Earnings Transcript
  • Q4 2025 Earnings Call Transcript
  • Q3 2025 Earnings Call Transcript
  • Q2 2025 Earnings Call Transcript
  • Q1 2025 Earnings Call Transcript
Research Document
  • CourtListener Litigation Search — 10 cases (incl. Ritchie derivative C.A. 2022-0102-BWD)
Web Source
  • Greenhouse Job Postings — 43 listings (commercial buildout signals)